Full Year Results 

Abcam falls on expansion plans

Abcam falls on expansion plans

A July trading update from Abcam (ABC) had already teased its next expansion phase, garnering an unenthusiastic response from investors. With more details unveiled alongside full-year results – as well as a £13m hit to statutory earnings from previous software development costs – the antibody specialist saw its shares tumble 9 per cent on the day.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now